GConferenceGridThe Conference Catalogue · Vol. 2027Folio № 732D7D
Of the Field

Festival of Biologics USA 2027

T

he Festival of Biologics USA is America’s most comprehensive biologics event, covering the entire industry from antibody therapies, cell and gene therapies, immunotherapies, to biosimilars. It brings together 2,000+ attendees from pharma, biotech, start-ups, academia, regulators and investors for two days of presentations, panels, networking, and workshops.…

Visit the official site
16Voices
29Underwriters
0Exhibitors
0On the bill · sessions
30Companies · in total
§I

The Voices

Programmed at Festival, in alphabetical order.
Anne Kerber
Senior Vice President, Head Cell Therapy Development · Bristol Myers Squibb
Chris Mason
Professor of Cell and Gene Therapy · UCL
Emanuela Lacana
Deputy Director, Office of Therapeutic Biologics and Biosimilars/ OND/ CDER · FDA
Eugene Zhukovsy
Vice President and Site Head of Biologics R&D · Orion Pharma
Gillian Woollett
Head of Regulatory Strategy & Policy · Samsung Bioepis
Isabell Remus
Global Head of Biosimilars · Sandoz
Jane Seagal
VP of Antibody Discovery · AlivaMab Discovery Services
Jay Mandrekar
Professor of Biostatistics & Neurology · Mayo Clinic
John Lambert
Independent Consultant, Former EVP and CSO · Immunogen
Karin Jooss
Founder & Chief Scientific Officer, Gritstone Bio, Executive Vice President & Head of Research & Development · Fate Therapeutics
Marjorie Shapiro
Former Chief, Laboratory of Molecular and Developmental Immunology · FDA
Michael Zaiac
Head of Medical Affairs Oncology Europe and Canada · Daiichi Sankyo
Prasad Adusumilli
Deputy Chief, Thoracic Surgery, Vice Chair, Department of Surgery · MSKCC
Prasun Chakraborty
Founder & CEO · Genevation LTD
Prof. Sir Gregory Winter
2018 Nobel Laureate in Chemistry
Rebecca Sendak
Head (SVP) Global Large Molecules Research Platform · Sanofi
§II

Underwritten By

The houses behind the program. Tiers as disclosed.
AbbVie
AlivaMab Discovery Services
Amgen
Arscientia
Biogen
Bristol Myers Squibb
Diachi Sankyo
Exreprotein LLC
Fate Therapeutics
FDA
Fujifilm
Genentech
Genevation LTD
Gilead
Gritstone Bio
Icosagen
Immunogen
Mayo Clinic
MSKCC
Novartis
Orion Pharma
Pfizer
Samsung Bioepis
Samsung Biologics
Sandoz
Sanofi
Tavotek Biotherapeutics
UCL
UCSD
Intermission
Part the Second · For the Buyer

What does it mean when 30 companies show up — and 13 bet on three roles at once?

“30 companies. thirteen are betting more than once.”

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

№ 01Fig. 01 — Composition of the House
13All threespeak · spons · exh
16Sponsoringsponsor only
0Exhibitingexhibitor only
1Speakingspeaker only

The Triple-Threat

FDA·AlivaMab Discovery Services·Bristol Myers Squibb·Fate Therapeutics·Genevation LTD·Immunogen·Mayo Clinic·MSKCC·Orion Pharma·Samsung Bioepis·Sandoz·Sanofi·UCL

№ 02Fig. 02 — The Voices, by Seniority

69% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

  • C-suite213%
  • VP-level531%
  • Director / Head of425%
  • Other roles531%

Of 16 on the bill · classified by free-text title

№ 03Fig. 03 — The Heaviest in the Room
  1. 01FDASp2V
  2. 02AlivaMab Discovery ServicesSp1V
  3. 03Bristol Myers SquibbSp1V
  4. 04Fate TherapeuticsSp1V
  5. 05Genevation LTDSp1V
  6. 06ImmunogenSp1V
  7. 07Mayo ClinicSp1V
  8. 08MSKCCSp1V
  9. 09Orion PharmaSp1V
  10. 10Samsung BioepisSp1V
  11. 11SandozSp1V
  12. 12SanofiSp1V
  13. 13UCLSp1V
  14. 14AbbVieSp
№ 04Fig. 04 — By Tier
unspecified29
100% of 29
№ 06Fig. 06 — Adjacent Convocations · by shared underwriters